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and found that >60% of CAPAN1 and >40% of DU145 were
killed after an initial treatment but were resistant to subse-
quent treatment. Importantly IHC analysis of these resistant
tumor cells demonstrated lack of expression of the targeted
antigen, MUC1. This observation was conﬁrmed in an artiﬁ-
cial model using 293T cells engineered to express either
MUC1 (mOrange+) or PSCA (GFP+), which illustrated an
exquisite speciﬁcity of T cells but at the same time a weak-
ness when targeting a heterogeneous tumor cell population.
Therefore we generated a second CAR targeting the TAA
PSCA, and demonstrated stable expression on primary T cells
(892%), whichwere able to kill the PSCA+ cell lines, CAPAN1
and DU145, with no effect on control PSCA- 293T, (486%,
4146% and 42% speciﬁc lysis, respectively, 10:1 E:T).
Finally, we assessed the anti-tumor effects when both CAR-
modiﬁed products were combined. When tumor cells
expressing both TAAs were treated with CAR-MUC1 + CAR-
PSCA T cells we saw additive anti-tumor effects with 7610%
killing of CAPAN1 compared with only 356% and 486%,
respectively, using CAR-MUC1 and CAR-PSCA T cells indi-
vidually. We saw similar results using our engineered 293T
tumormodel. Hence the combination of CARs that target two
distinct TAA expressed on cancer cells (PSCA andMUC1) may
prevent tumor immune escape and enhance the potency of
adoptive T cell transfer.478
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Background: Medulloblastoma is the most common brain
tumor in children and its prognosis is improved by the
combination of surgical resection, irradiation, and/or
chemotherapy. Chemotherapy followed by autologous
peripheral blood stem cell (auto-PBSC) rescue has been used
for the treatment of high-risk medulloblastoma.
Patients & Methods: Between July 2010 and July 2012, 8
patients with high-riskmedulloblastoma underwent tandem
chemotherapy with stem cell rescue procedures imple-
menting one of two protocols. Four children aged less than
36 months old [median age 30 month old (range 24-33
months old)] (group-A) received the Children's Oncology
Group e ACNS0334 protocol. The other 4 patients aged more
than 36 months old [median age 12 year old (range 9-15
years old)] (group-B) were treated according to the St. Jude -
SJMB03 protocol.
Results: All patients engrafted well and are alive with no
evidence of disease. Median follow-up from discharge for
last transplant is 6.5 months (range 3-24 months). Neither
cardio nor pulmonary toxicities were documented. Gastro-
intestinal tract: No patient had veno-occlusive disease of the
liver. All patients developed mild to moderate mucositis,
thus received total parentral nutrition for a median period of
7 days (range 5-12 days). Infections: group-A: all patients
experienced at least 1 transplant period without any fever.
Bacteremia included staphylococcus Coa. (-), proteus sp. and
pseudomonas sp. Neither viral nor fungal infections were
documented. Group-B: 2 patients experienced at least 1
transplant without any fever. Bacteremia included staphy-
lococcus Coa. (-), staphylococcus aureus and pseudomonassp. Metabolically: 2 group-B patients developed inappro-
priate anti-diuretic-hormone secretion. All patients devel-
oped mild hypomagnesaemia. Neurology: 1 group-B patient
developed generalized motor weakness attributed to MESNA
he received for the cytoxan. From then on, cytoxanwas given
without MESNA but with urinary catheterization and
hyperhydration. He also developed mastication movements
attributed to the resperidal he got, which was stopped with
improvement. No patient developedmajor bleeding. Renal: 1
group-A patient received VP-16 instead of carboplatine on
the ﬁrst transplant due to basic renal impairment. 1 group-B
patient suffered from renal impairment with GFR reduction
between 25%-50% of baseline following his ﬁrst transplant.
He also demonstrated grade-3 ototoxicity and thus received
only 50% cisplatin dose from the third transplant. Another 2
group-B patients suffered from grade 4 ototoxicity before
admission and therefore did not get cisplatin at all.
Conclusions: Tandem auto-PBSC transplants are feasible for
high-risk medulloblastoma pediatric patients, with excellent
engraftment and survival results and acceptable toxicities,
applying the ACNS0334 and SJMB03 protocols.479
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Adoptive T-cell immunotherapy for solid tumors though
promising has shown limited efﬁcacy in clinical studies. The
hindrance to achieving an objective and durable therapeutic
response is, in part, mediated by the dynamic nature of the
tumor and its complex microenvironment. Tumor-directed
therapies fail to eliminate components of the microenvi-
ronment, which can reinstate a tumorigenic milieu and
contribute to recurrence. Cancer associated ﬁbroblasts
(CAFs), the most preponderant cell type in the microenvi-
ronment, contribute to desmoplasia, tumor growth and
therapeutic resistance. CAFs express ﬁbroblast activation
protein alpha (FAP), a membrane bound serine protease, in
a number of a solid tumors making it an attractive immu-
notherapeutic target. We hypothesized that targeting CAFs
with FAP-speciﬁc T cells will destroy the 'tumor promoting
haven', resulting in signiﬁcant anti-tumor effects.
To test this hypothesis, we successfully generated FAP-
speciﬁc T cells using a second-generation chimeric antigen
receptor (CAR) speciﬁc for FAP. A prototypical CAR combines
the antigen speciﬁcity of an antibody with the signaling
function of a T-cell. The resulting genetically engineered FAP-
speciﬁc T cells recognized and killed human as well as
murine FAP-positive target cells ex vivo. FAP-speciﬁc T cells
also led to a signiﬁcant decrease of FAP-positive murine lung
stromal cells with a concomitant reduction in A549 lung
tumor growth and improved survial when administered
systemically into SCID mice. Targeting FAP-positive CAFs
alone, therefore induces a signiﬁcant anti-tumor response
indicative of its important role in tumor progression.
Finally, given the reciprocal relationship between tumor cells
and CAFs, we hypothesized that co-targeting these two
compartmentswould result in enhancedanti-tumor response
